Klow 80mg (Blend) yu gi oh.

▎ Wetin na BPC-157?

BPC-157 na sεntetik pεptida we kכmכp fכ 15 amino asid dεm. in sikεns de kכmכt frכm di bכdi protεkshכn kכmpawnd (BPC) fragmεnt insay di hכman gεstrik mכkus protin dεm, we de wok lεk artifishal analכg fכ di εndojεnik gεstrointestinal protεktiv pεpti dεm. di kכr bayolojikal kכntribyushכn fכ dis pεptida de insay in pכtεnt tisu ripa rεgεdyushכn kapasiti. i de promuot proliferashכn εn maygrεshכn fכ ripa-rεlatεd sεl dεm lεk fכblas εn εndoteyl sεl dεm bay we i de aktibכt tayrosin kinaz rεsεpכta dεm (εgz., c-Met), we i de aksεlεrayt sεntesis εn rimodelin fכ εkstrasεlula matris kכmכpכnεnt dεm (εgz., kolagen, fibronectin). dis ifekt dεn bin validet am insay mכdel dεm fכ gεstrointestinal כlsa, tεndon rכpchכ, εn bon dεfεkt. insay di gastric mכkus injuri mכdel dεm, BPC 157 de sכt di tεm we di כlsa de hεl bכku bכku wan εn i de impruv di mכkus rigεnεreshכn kwaliti.

BPC 157 de du wan kכl rol bay we i de mכdulet di inflammatory maykro envayroment. i de sכpres nyutrofil infiltreshכn εn di כva εksprεshכn fכ pro-inflammatory fכktכ dεm (lεk IL-1β εn NF-κB), we di sem tεm de upregulate di sekreshכn fכ anti-inflammatory fכktכ dεm (lεk IL-10). dis de mitigate di akyu inflammatory rεspכns we de fכlכ injuri εn i de mek sεkכnd tisu dεm we dεn nכ de kכntro di inflameshn we dεn nכ kכntrol. di vasoprotektiv ifekt dεm we i de gi kin sho klia wan. bay we i de mek di vaskulכr εndoteyl growth fכktכ (VEGF) εn angiopoietin kכmכt, i de mek nyu vaskulεr nεtwכk fכm na di εria dεm we dεn dכn pwεl, i de mek di lokal blכd pεrfyushכn bכku, εn i de gi di rayt nyutriεnt εn כksijεn saplai fכ di tisu ripa.

▎ Wetin na KPV?

KPV, we na tripεptida we kכmכp fכ laysin-prolin-valin, de kכmכt frכm di C-tεrminal rijyכn fכ α-melanosayt-stimulεt כmon (α-MSH) εn na nכchכral fragmεnt we de kכmכt wit signifyant bayolojikal aktiviti.

insay inflameshn rεguleshכn, KPV de sho pכtεnt anti-inflammatory aktiviti. i de ifektivli sכpres di nyuklia fכktכ-κB (NF-κB) signal path, i de ridyus di transkripshכn εn rilis fכ pro-inflammatory saytokεn dεm (lεk IL-1β, TNF-α, εtk), we de kכb inflammatory kaskad dεm na dεn sכs. insay animal mכdel dεm fכ kolεt, we dεn gi KPV bay mכt i de ridyus di intestinal inflameshn lεvεl dεm bכku bכku wan εn i de mek di mכkus dεm we dεn dכn dכn sכmtεm. dis ifekt kכmכt frכm in prεsis rεguleshכn fכ inflammatory signal in intestinal imyun sεl dεm εn εpitεlial sεl dεm. KPV de mitigate lokal inflammatory rispכns dεm fכs bay we i de stεbyul di mast sεl dεm εn i de ridyus di rilis fכ inflammatory mεdiate dεm lεk histamin, we de mek i de mεnten di tisu homכstasis.

na di imyun rεgulεtכri lεvεl, KPV de sho baydayrεkshכnal mכduleshכn kεpabiliti. i de εnhans di T-sεl difrεns εn fכnshכn, i de protεkt di sekreshכn fכ imyun rεgεdyushכn fכktכ dεm lεk IL-2 εn IFN-γ, εn i de bכst di sεl imyun rεspכns dεm. insay כtoimyun sik mכdel dεm, KPV de rεgεl Th1/Th2 sεl bεlε, i de ridyus di כtoimyun riakshכn dεm we pasmak, εn i de mek di imyun dεm nכ damej.

KPV de ol pכtεnshal valyu bak fכ sεl proliferashכn εn tisu ripa. bay we i de aktibכt di rilevεnt intasεlulyar signal path dεm, i de protεkt di fibroblast proliferashכn εn maygrεshכn, i de aksεlεrayt di sεntesis fכ di εkstrasεlula matris kכmכpכnεnt dεm lεk kolagen, εn i de mek di wund hεl insay tisu dεm lεk skin εn mכsul. insay skin ripa εkspεriεns, KPV-trit wund dεm sho signifyant aksεlεrayt hεlin rεt εn rεdכks ska fכmeshכn, we sho in pכsitiv impak pan tisu ripa kwaliti. KPV kin mek bak di εksprεshכn fכ di angiojεnεsis-rεlatεd fכktכ dεm lεk vaskulεr εndoteyl gכt fכktכ (VEGF), we de protεkt nyu vaskulεrayzeshכn εn impruv bכdi saplai to sayt dεm we injuri, we de gi imכtant kכndishכn fכ di tisu rigεnεreshכn.

▎ Wetin na GHK-Cu?

GHK-Cu na komplεks we glycyl-L-histidyl-L-laysin tripεptida εn kכpa ayכn dεm de fכm. leva di sinagεstik akshכn fכ kכpa ayכn dεm εn di tripεptida, i de du mכltipכl krichכl fכnshכn dεm insay fysiolojikal aktiviti dεm. insay di skin ripa εn rijenereshכn, i de akt lεk signal pεptida fכ mek di fibroblast dεm fכ sכntez kolagen, elastin, εn glycosaminoglycans, we de mek di skin fכm εn elasticity we i de impruv di skin ishu dεm we kכz fכ ol כ fכto ej. di tεm we di wund de hεl, i de mek di stratum kכniכm sεl gro fכ aksεlεrat di kכloshכn we i de rεgεl inflameshn bay we i de sכpres di εksyכsiv IL-6 εn TNF-α εksprεshכn. i de promuot bak di makrofag agregεshכn fכ rilis di growth fכktכ dεm, we de εp fכ ripa di tisu dεm εn rimכdelin. di pawaful antioksidant εn anti-inflammatory prכpati dεm we i gεt de rεgεl di intasεlulyar kכpa lεvεl, i de εnhans di antioksidant kapasiti, εn delay di sεl dεm we de ol. insay pulmonari inflameshn mכdel dεm, i de mitigate lipopolysaccharide-induced akyu lכng injuri εn impruv di tisu inflammatory stet dεm. GHK-Cu de bεnεfit di ia hεlth bay we i de mek di ia fכlikul sεl dεm wok, i de mek di melanin prodyuz, i de rεgεl di εnεji mεtabolism, εn i de εp fכ mek di ia lכs bכku.

Dɔn

as blεnd fכ TB 500, BPC-157, KPV, εn GHK-Cu, Klow in sinagεstik ifekt dεm de sho tru di כvalap εn komplimentari rεguleshכn fכ mכltidimεnshכnal fysiolojikal fכnshכn dεm. TB 500 de promuot sel maygrεshכn εn angiojεnεsis, BPC-157 de εnhans tisu ripa εn inflammatory rεguleshכn, KPV de fכkus pan imyun bεlε εn lokal anti-inflameshכn, we GHK-Cu de fכnshכn in antioksidant difεns, skin rigεnεreshכn, εn maykro envayroment optimizεshכn. tכgeda, dεn de fכm wan klos-lכp sistεm fכ 'ripa-anti-inflameshכn-imyun mכduleshכn-maykro envayroment εnhansmεnt.'

כnda dis sinagεji, TB 500 εn BPC-157 de aksεlεrat sεl proliferashכn εn matris sεntesis, we KPV de mitigate pasmak inflameshn bay we i de inhεbit di NF-κB path, we de mek wan stebul envayroment fכ ripa. GHK-Cu in antioksidant prכpati dεm de ridyus fri radikal dεmεj to nyu fכm tisu dεm, εn in vasoprotektiv ifekt dεm de sinagεj wit TB 500 in angiojεnεsis fכnshכn fכ εnhans lokal bכdi saplai. KPV in baydayrekshכnal imyun mכduleshכn de bεlε di imyun aktibכshכn we BPC-157 εn GHK-Cu de trigεr, we de mek imyun disrεgulεshכn nכ de. dis sinaji nכ de כnli sכt di tisu ripa saykl dεm bכt i de impruv di ripa kwaliti εn ridyus di risk fכ fכm ska, we de gi kכmprεhεnsiv rεgεdyushכn advantej dεm lεk wund hεl, krεse inflameshn, εn skin ol.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.